Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases.

Interestingly, the frequency of atyMBCs had a decreasing trend (29.5 (21.2–35.2)% vs. 23.3 (18.8–31.0)%, p >0.05) ( Fig. 4C ) and the frequency of rMBCs and intMBCs increased after booster vaccination ( Supplementary Fig. 4A–C ).

also in 31,838 other papers